Related Experiment Video
Updated: Oct 9, 2025
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
Published on: January 7, 2019
TLR9/NF-kB Pathway Regulates Brucella CpG DNA-mediated Cytokine Response in Human Peripheral Blood Mononuclear Cells
Yunzhi Peng1, Wenhui Bai, Zhanli Wang
1Inner Mongolia Key Laboratory of Disease-Related Biomarkers, Baotou Medical College, Baotou 014030, China.
Background:
It was reported that targeting the Toll-like receptor9 (TLR9) signaling pathway can be a promising therapeuticstrategy forinterventions in various inflammatory and infectiousdiseases. However,it was not known whether the human TLR9 isresponsive to Brucellacytidine-phosphate-guanosine (CpG) DNAsequences and activatesthehost's innate immune system.
Objective:
The present study aimed to identify the novel humanTLR9agonists from Brucella CpG oligodeoxynucleotide(ODN) candidatesand verify their immune response regulatorymechanisms.
Methods:
Molecular docking methods were used to discover potentagonists of the human TLR9. The potential molecules were furthervalidated by Western blot and enzyme-linked immunosorbentassay(ELISA).
Results:
The experiment results showed a strong interactionandgood compatibility between the human TLR9 and BrucellaODN-1molecule. In addition, the induction of immune response byBrucella ODN-1 is a CpG-specific response. Moreover, the effectsof Brucella ODN-1 on cytokine response are dependent on theTLR9-mediated NF-κB pathway.
Conclusion:
These results indicated that the Brucella ODN-1 molecule canserve as a starting point to discover or designmore potent and specific TLR9 agonists that have the potential usein the treatment of infectious diseases.
Insights
Researchers identified Brucella ODN-1 as a novel agonist for human Toll-like receptor 9 (TLR9). This molecule activates the innate immune system via the TLR9-mediated NF-κB pathway, offering potential for treating infectious diseases.
Area of Science:
- Immunology
- Microbiology
- Pharmacology
Background:
- Targeting Toll-like receptor 9 (TLR9) signaling is a promising therapeutic strategy for inflammatory and infectious diseases.
- The response of human TLR9 to Brucella CpG DNA sequences and its activation of the innate immune system were previously unknown.
Purpose of the Study:
- To identify novel human TLR9 agonists from Brucella CpG oligodeoxynucleotide (ODN) candidates.
- To verify the immune response regulatory mechanisms of these candidates.
Main Methods:
- Molecular docking was employed to discover potent human TLR9 agonists.
- Potential molecules were validated using Western blot and enzyme-linked immunosorbent assay (ELISA).
Main Results:
- Brucella ODN-1 demonstrated strong interaction and compatibility with human TLR9.
- Immune response induction by Brucella ODN-1 was confirmed as a CpG-specific response.
- The effects of Brucella ODN-1 on cytokine response were dependent on the TLR9-mediated NF-κB pathway.
Conclusions:
- Brucella ODN-1 serves as a valuable starting point for developing more potent and specific TLR9 agonists.
- These agonists hold potential for the therapeutic treatment of infectious diseases.
More Related Videos
15:29Microscopy-based Assays for High-throughput Screening of Host Factors Involved in Brucella Infection of Hela Cells
Published on: August 5, 2016
10:57NF-κB-dependent Luciferase Activation and Quantification of Gene Expression in Salmonella Infected Tissue Culture Cells
Published on: January 12, 2020
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:16TGF - β Signaling Pathway